Member Info for CHELSEA7

33k

Should go blue soon, tiny volumes

And that delayed trade still not showing. Dummy bid now 11.555

Should be about 14.19, trade 13.19

Tick Down 11/12.....................and bid 11.40

And Full Ask Paid...............12p

11.50/12

+2.17%

Compoundinterest, I agree, and people are taking advantage of these prices

At 11.91........................not delayed and as I said buyers about.

Ivy, the charts were not signalling a bear reversal either, we slipped from 18p to 15p and they were still showing 100% buys as they were predicting 26p. It was only at 14p they were saying in the short term it was a sell, medium and long term 30-90 days still 100% buy.

Looking back most of the night on many posts I have missed the last week or so, I get the impression there is a fair deal of confusion as to the role of COVIDITY in the wake of the Pfizer announcement and a couple of others since and more will follow. So I appreciated your responses ro crackins post which I strongly disagree with........................

""Clearly the SP has been hit with the news of others making significant progress with Covid vaccines while Scancell sleep walks into trials. Not sure why we are initiating a Phase 1 clinical trial known as COVIDITY during 2021. That seems a lost cause for momentum, market impact and SP value. I suppose we have to progress given the capital injection to do the research.

Do we really believe there is now a market for long term protection and that Scancell are leading the pack? I doubt it. Time will tell but it looks like Covid is a short term negative for those buying in at 13p and above. Question is, where is the bottom?""

Ivy, I noticed you recommended that post, do you really think that is the case, Im surprised. Meanwhilst we have had that £2.7m funding from U.K. Government and it would seem there could be more in the pipeline which I feel will position us well and prove up Immunobody in the process. A dreadful thought but we just don"t know how powerful these vaccines will prove to be, and what may be around the corner, but in the meantime we are setting up well for a position when it comes to infectuous diseases. I think it is a bit early to price condition our value for now until the New Year, one of the reasons is that we seem to have a few building holdings, I have a feeling Vulpes will, and I just wonder whether Redmile have plans for another party to build a holding as they have reached 29.97% already. Time will tell, but further drift is not a foregone conclusion IMHO.

Scancell Holdings plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce the appointment of Susan Clement Davies as a Non-Executive Director of the Company with immediate effect. For health reasons, Dr Alan Lewis is standing down from the Board as Non-Executive Director with immediate effect.



Susan is an experienced life sciences financier with over 25 years of capital markets and investment banking experience, including Managing Director of Equity Capital Markets at Citigroup Global Markets Limited and most recently until 2018, Managing Director at Torreya Partners LLC, a global investment banking firm serving companies in the Life Sciences industry. Her work at this time included providing advice on M&A, corporate finance, licensing transactions and pharmaceutical asset sales, with clients ranging from large pharmaceutical companies through to private equity firms focused on healthcare. Susan is currently Non-Executive Director and Chairman of the Audit Committee of Evgen Pharma plc, an AIM listed clinical stage drug development company.



Commenting on the appointment, Dr John Chiplin Chairman of Scancell, said:



"On behalf of the Board, I would like to take this opportunity to thank Alan Lewis for the contributions he has made to the Company since he was first appointed to the Board in 2016 and wish him all the best for the future. In addition, I am very pleased to welcome Susan to the Board of Scancell. Susan's considerable experience in investment banking will be invaluable for any potential future licensing and corporate transactions."



Susan Clement Davies commented:



"I am delighted to be joining the Scancell Board at this very exciting time and look forward to working with the team to maximise the potential value of the Company's platform technologies."

So in addition to the 3/4 positions for scientists (PhDs), it more than seems we are going it alone and taking our yearly ependiture from £5.5m to £7m as I feel we will be employing two new key members s Team Leaders if as I suspect we have particular teams working on Immunobody, Moditope and Covidity. This was the plan laid out by JC some time ago, but we have done it gradually as funds become available, not something we could have done on £5/6m raises as in the past

I am so pleased with this news and if we are to follow Biontech a listing on NASDAQ in maybe 2.5 years will be on the cards and it is ironic there first Approvals could come from COVID 19 as indeed ours could, but we would be more a Global name for that to happen as we join the world of IPOs and future major funding opportunities. At least during delays this year, which everyone has had we have given so much thought to the future and I a deighted with the outcome, so far, and feel a sense we have new buyers in the market picking up large tranches as PIs retreat for now. No plans to sell myself, not at these levels.

Dr Robert Miller is a Managing Partner in Artemida Pharma, a drug development consultancy and has represented a number of companies providing strategic expertise, medical management and clinical development support for both small and large pharmaceutical and biotechnology companies during his 30-year career in the industry, particularly in the fields of oncology and immune-oncology.



Robert is a fellow of the Royal College of Surgeons, Faculty of Pharmaceutical Medicine and the Royal Society of Medicine. He is also a member of the European Society of Medical Oncologists and affiliate member of the American Society of Clinical Oncologists. Robert received his medical training at The London Hospital Medical College and has held a number of surgical and medical appointments across various hospitals in the UK.



The clinical expertise that Gillies and Robert bring to Scancell will complement the existing research and development activities led by Professor Lindy Durrant, Chief Scientific Officer, and Dr Sally Adams, Chief Development Officer.



Dr Cliff Holloway, Chief Executive Officer of Scancell, commented:



"We are delighted to welcome both Gillies and Robert into their roles at Scancell. Their extensive experience in clinical development within the sector will be invaluable as we progress our pipeline of products through the clinic and towards commercialisation. Following our recent successful fundraises, our initial focus is to progress the clinical development of Modi-1 and SCIB1, in addition to starting our COVIDITY clinical trial in 2021. We are excited by the advice and guidance that Gillies and Robert will be able to provide in advancing these trials and look forward to working with them."



Dr O'Bryan-Tear, Chief Medical Officer of Scancell, commented:



"I am delighted to be joining Scancell with my colleague Robert Miller at this critical time in the evolution of the Company. With first class, innovative science, and a recent successful series of fundraisings, the Company is poised to exploit this world leading technology to the full in the clinical arena. Robert and I look forward to advancing this clinical development effort and enabling the Company to reach important clinical milestones in the coming years."

And then we have the very underrated appointment of Susan Clement-Davies........................

TBC:(

Still ploughing my way through the events of AGM2 week, and it was hard to predict what we might hear in the second one, I had just felt particularly, since we initiated the SCIB1/Keytruda trial but did not manage to enrol any patients, what we do differently this time around, what were the endpoints and how much influence as a small AIM Biotech we had to get referrals from Consultants to our trials and make this time less problematic. We had heard about four new sites but if there were issues and more fundamental problems they would just have been magnified by four times.

I had been hoping for some kind of tie up with a Big Pharma, especially since Redmile came in, to see us through trials and to be able to use resources we just didn" have, so I am delighted with the Appointments of Dr Gillies and Dr Robert Miller as those concerns have been addressed without needing to take anything away from in house at this early stage. From the RNS...............

Appointment of CMO and Medical Director
Tue, 17th Nov 2020 12:00

RNS Number : 6038F
Scancell Holdings Plc
17 November 2020

17 November 2020



Scancell Holdings plc

("Scancell" or the "Company")



Appointment of Dr Gillies O'Bryan-Tear as Chief Medical Officer and Dr Robert Miller as Medical Director



Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, is pleased to announce the appointments of Dr Gillies O'Bryan-Tear to the position of Chief Medical Officer and Dr Robert Miller to Medical Director. Today's appointments reflect Scancell's continuing focus on advancing the clinical development and commercialisation of its programmes for the treatment of cancer and in developing a vaccine for COVID-19.



Dr Gillies O'Bryan-Tear has over 30 years' experience in the pharmaceutical industry, spanning clinical development, medical management and commercial roles. He has held senior leadership roles in large and small pharmaceutical and biotechnology companies, in the US and Europe, and has been involved in multiple product approvals. In 2009 he became Chief Medical Officer of Algeta, a listed Norwegian biotech company developing a radiopharmaceutical for prostate cancer, which was launched worldwide in 2013. Algeta was subsequently acquired in 2014 by Bayer for $2.9 billion. Following the acquisition, Dr O'Bryan-Tear has been a retained adviser to a number of global biotechnology companies including Audentes before its acquisition by Astellas, as well as Fusion Pharmaceuticals and Clarity Pharmaceuticals.



Gillies is a Fellow of the Faculty of Pharmaceutical Medicine in the UK and is Chair of its Policy and Communications Group, as well as a Fellow of the Royal College of Physicians. He obtained his MD degree from the University of Cambridge and University College Hospital, London and trained in internal medicine and oncology in the UK.

TBC:(

WTP, exactly, all these details made me think the outcome would end up with a Big Pharma, and to meet our needs to take our lead candidates through trials.

I wonder how lomg it has taken to get the quality of new employees together to ensure we keep this as an in house operation for now and through Phase 1 trials. Alot of planning has gone into this and the raising and I gues we have had the best part of the year to plan accordingly. Reading up on the share chat since the weekend, the employees their CVs etc and can"t help feeling excited at the confidence coming from the BOD for now and the foreseeable future. We really have stepped up as a company with a M/Cap of circa £100m, cash in the bank andunfortunately I have missed this week largely but have moticed some hefty buys, I wonder whether Vulpes will use this opportunity to buy a considerable amount in the market, and I guess with all the financial input the company has been afforded it has attracted new big buyers to the share, and i just wonder whether another vehicle will be used by Redmile to increase their holding like Vulpes can despite holding 29.97% already, certainly a special year to look ahead to, and from my perspective all the new astaff appointed should make quite an impact as they are all in areas we have commented on to various degrees, were needed IMHO, and if we can just get these trials started we will have constsnt flows of data all through the coming year. Bestof luck to all at Scancell, we have come a very lomg way in just the recent few years.

Included this piece on Scancell........................

/www.valuethemarkets.com/2020/11/19/the-second-gen-covid-19-stocks-offering-explosive-opportunities-2/

GN

""Do we really believe there is now a market for long term protection and that Scancell are leading the pack? I doubt it.""

Om the contrary, as Burble and Bermuda suggested we are on the journey to prove that and we are not limited just to Covid 19. Government funding suggests that too, there must have been many failed applications but we got £2.7m for its potential, memory lasting T-Cells for longer protection. looking forward ro seeing how this reflects in data. GN Guys, and thanks for your time Burble, very informative

Burble

Thanks for your reply. Yes, it has been on my mind for quite some time whether we had the necessary persommel to overseer trials, and as you say put in place the necessary endpoints to help stimulate commercial success. Hence why I felt some kind of tie up with a 3rd party would be somewhat beneficial.

It seems like at this stage anyway we have decided to address that in house and further help the development of new candidates. We just need to clear this log jam in the pipelince, i.e get trials underway, are you aware what the wider market in general are planning to get clinical trials back on track, dependant or not on the coronavirus?

Strategy post-Redmile funding initiative
Redmile recognised the broad utility of Scancell’s technologies and development pipeline. It also appears to wish
to take advantage of an apparent ‘scientific arbitrage’ opportunity that seemingly has been created between the US
and Europe, in terms of recognising the different levels of scientific value allocated to innovative drug development
technologies/initiatives and the teams driving/supporting them in different geographical locations. Within this, it
recognised a major and continuing drag on successful development and its associated commercialisation due to
the lack of adequate and immediately funding, perhaps resulting from a relatively pedantic ‘drip-feed’ European
approach to extending/progressing necessarily costly clinical and/or tech-intensive projects. Having selected such
‘winners’, the contrasting ‘US approach’ adopted by Redmile instead, is to inject significant ‘transformational’ cash
funding (in either straight equity, CLNs or a mix of the two) that can be rapidly put to work in order to resource and
accelerate existing programmes, while also seeking to seize opportunities unique technologies might present and
in tandem broadening pipelines sufficiently to capture a larger proportion of the inherent value, rather than
externalise the assets too early through royalty or milestone-based sales to larger, better-resourced development
partnerships.
Scancell had initially sought development funding sufficient to carry its key developments, SCIB1, Modi-1 and the
COVID-19 project, through their planned clinical studies. Following a subscription (in the form of equity and CLNs)
from Redmile, along with participation in the form of a CLN and participation in a placement from existing core
shareholder, Vulpes, together with a £2m equity open offer to qualifying existing shareholders, in August 2020 it
raised £15m gross. Subsequent to this, Scancell management received and recommended a further significant
proposal from Redmile, this time to subscribe an additional £30m to the Company (again in the form of equity and
CLNs), the larger proportion of which would be subject to shareholder approval. A further £3m equity open offer to
qualifying shareholders (again recognising that existing shareholders might wish to participate on terms identical
to the equity subscription) was also heavily oversubscribed, effectively thereby securing shareholder approval for
the course of action being taken. In total, since the beginning of Scancell’s new financial year to end-April 2021,
new funds raised have amounted to £48m (gross).

Buys 311k

Sells 287k

-2.13%

Thyanks cossie, haven"t seen a research note from them before...................

Use of Funds
The pool of funds now raised will allow Scancell to extend the utility of its
ImmunoBody®
, Moditope® and AvidiMab™/TaG antibody products and platforms,
while also accelerating and broadening its development pipeline of new potentially
novel therapies. It will provide flexibility regarding development plans for its
existing pipeline to ensure both optimal development and commercialisation
strategies can be pursued, thereby limiting the potential impact of economic
pressures caused by COVID-19. More specifically, while being expected to rapidly
move its COVID-19 DNA vaccine development programme forward, Scancell is
ideally positioned to progress its lead product, SCIB1, which has already initiated its
Phase II clinical study in melanoma, aiming to enrol a total of 25 patients, while
also completing the preparation of GMP supplies required for regulatory
submission to initiate Modi-1’s planned UK Phase I/II clinical study in H1 2021.

Sounds good to me

Enjoyed your posts today, thanks.

How do you see these two latest additions of Scancell, being the Chief Medical Officers in relation to trials and recruitment of patients, and for future development of candidates. One of my concerns was as we saw earlier this year we were struggling to enrol any patients to the SCIB1/Keytruda trial?